Odd Lots

By and large, American households are in a healthy economic position. Yes, unemployment has been rising, but it's still at fairly low levels. Consumer spending has held up well despite terrible sentiment. And many households are sitting on huge stock market gains and have a big home equity cushion. And yet, there are signs of trouble. Most notably, auto loan delinquencies have been surging to their highest level in history. It's the same with student loans, where delinquencies are far higher than normal. So what's going on? On this episode, we speak with Rikard Bandebo, the chief economist at VantageScore, which offers a consumer credit score that's different from the traditional FICO measures. He explains how surging prices, rising interests, and -- crucially -- rising insurance costs have created an auto squeeze. We also discuss what this means for broader consumer health and whether this auto delinquency phenomenon signals something broader about consumer stress. Read more:Rise of the ‘Zombie’ LoansFirst Brands Asks Lenders for Fresh Cash of Up to $800 Million Only Bloomberg - Business News, Stock Markets, Finance, Breaking & World News subscribers can get the Odd Lots newsletter in their inbox each week, plus unlimited access to the site and app. Subscribe at  bloomberg.com/subscriptions/oddlots Join the conversation: discord.gg/oddlotsSee omnystudio.com/listener for privacy information.

You probably already know someone doing peptides — the amino acids that form the basis of popular new drug treatments like Ozempic and Wegovy. Today there are peptides meant to help with everything from weight loss, to cellular regeneration, to improved eye contact while talking. In San Francisco, there are even organized “peptide raves.” Yet most of these underground peptides haven’t been approved by regulators for human use in the US. So where are they coming from? And how do they get here? On this episode, we speak with two guests who have seen this growing subculture up close, Jasmine Sun, an independent writer covering AI and San Francisco culture, as well as Zak David, managing partner of Pirsek Technologies, which runs a peptide supplier, Peptide Partners. Subscribe to the Odd Lots NewsletterJoin the conversation: discord.gg/oddlotsSee omnystudio.com/listener for privacy information.

The politics of AI are already exploding. Whether we're talking about data centers, electricity prices, labor displacement, water consumption, competition with China, or users of chatbots becoming psychotically obsessed, AI is already a major topic in elections. And since there's so much money at stake, the industry is already spinning up super PACs and lobbying arms. Last month, it was reported that a new $100 million AI-industry super PAC called Leading the Future would be directly targeting Alex Bores, a Democrat who is running for his party's nomination for New York's 12th congressional district. Why target Bores? Well, as an New York assemblymember, he has led the push for the regulation of AI at the state level. The industry, of course, views state-level regulation as an existential threat to their business. So on this episode we speak with Alex about how he views AI and the optimal approach to regulation. Alex also has a tech background, and so we talk about the technology more broadly, as well as other issues in contemporary politics.Subscribe to the Odd Lots NewsletterJoin the conversation: discord.gg/oddlotsSee omnystudio.com/listener for privacy information.

When we think about America’s economic rise, we usually point to agriculture or the industrial revolution. But in the early days of colonization, one of the biggest economic drivers wasn’t crops or factories — it was animal products. Deerskins were a booming trade that pushed hunters into new frontiers. In the early 1800s, beaver pelts became a fashion craze. And of course, later that century, we nearly hunted buffalo to extinction in another frenzy of resource extraction. On this episode, we talk to Steven Rinella, author and founder of MeatEater, about this overlooked chapter in US economic history, plus how the hunting economy functions today. Read more:USDA Lowers Cattle Price Outlook After Tyson Beef Plant ClosureRFK Jr. Eyes Single National Standard on Food Labeling and Safety Only Bloomberg - Business News, Stock Markets, Finance, Breaking & World News subscribers can get the Odd Lots newsletter in their inbox each week, plus unlimited access to the site and app. Subscribe at  bloomberg.com/subscriptions/oddlots Join the conversation: discord.gg/oddlotsSee omnystudio.com/listener for privacy information.

Most people think of venture capital as funding software startups or, these days, some new AI tool. But VC also plays a major role in developing new medicines and treatments. That’s the world of D.A. Wallach — though he didn’t start there. Before becoming a biotech investor, Wallach was the lead singer of the indie rock band Chester French. So how did he make the leap from music to venture capital? How does he spot promising biotech opportunities? What does it actually take to bring a new drug to market? And how does biotech investing differ from traditional VC? We talk to the co-founder of Time BioVentures about all of this — plus we get his thoughts on AI’s impact on music and a special performance.Have a question for Joe and Tracy?  Now's your chance to be the perfect guest  - record a voice memo with your name, age, location and question and email to [email protected] for a chance to be included in the holiday AMA episode.Read More:Big Pharma’s Patent Cliff Puts China Front and CenterNovartis Strikes Deal With UK Biotech for Up To $1.7 BillionJoin the conversation: discord.gg/oddlots Only Bloomberg.com subscribers can get the Odd Lots newsletter in their inbox — now delivered every weekday — plus unlimited access to the site and app. bloomberg.com/subscriptions/oddlotsSee omnystudio.com/listener for privacy information.